A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

NCT04958031 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

41

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision - Not Safety Related

Conditions

Apathy in Dementia

Interventions

DRUG: CVL-871 1.0 mg
DRUG: CVL-871 3.0 mg
DRUG: Placebo

Sponsor

AbbVie